Literature DB >> 29264317

Impact of the Immunogen Nature on the Immune Response against the Major HBV Antigens in an HBsAg and HLA-humanized Transgenic Mouse Model.

M Mancini-Bourgine1, G Guillen2, M L Michel1, J C Aguilar2.   

Abstract

Hepatitis B chronic carriage remains as a major public health problem. Protein and DNA vaccines are now widely used in therapeutic vaccine candidates. Although, the hepatitis B surface antigen (HBsAg) based vaccines have been largely studied, candidates comprising both HBsAg and core (HBcAg) either protein- or DNA-based approaches deserve further immunological characterization. In the present study, a repeated dose administration schedule for protein or DNA immunogens was conducted in order to characterize the resulting immune response in a humanized and HBsAg-tolerized setting. A novel transgenic (Tg) mice that express the HBsAg, human MHC class I (HLA-A*0201) and MHC class II (HLA-DRB1*01) molecules and devoid of endogenous murine class I and II molecules was used as a model of HBV chronic carrier. Mice were immunized by subcutaneous (protein) or intramuscular (DNA) routes and the humoral and cellular responses were evaluated. Protein or DNA immunization induced humoral immune responses against both HBsAg and HBcAg. The systematic analysis of epitopes that activate CD4+ and CD8+ T lymphocytes confirmed the accuracy of the model. Cellular immune responses were detected differing in their nature. CD8 T-cell responses were induced mostly after DNA immunization while CD4 T-cell responses were predominant in protein based immunizations. In addition, the intensity of HLA-A2-restricted CD8+ T cell responses was reduced in Tg mice expressing HBsAg when compared to control Tg mice. In conclusion, our results indicate that cellular immune responses necessary for the development of protective immunity can be achieved by DNA or protein immunization. However, important differences in their nature arise when immunogens are administered several times. How to cite this article: Mancini-Bourgine M, Guillen G, Michel ML, Aguilar JC. Impact of the Immunogen Nature on the Immune Response against the Major HBV Antigens in an HBsAg and HLA-humanized Transgenic Mouse Model. Euroasian J Hepato-Gastroenterol 2014;4(1):36-44.

Entities:  

Keywords:  Cellular immunity.; HBV; HBcAg; HBsAg; Humoral immunity; Immunogen; Transgenic mice

Year:  2014        PMID: 29264317      PMCID: PMC5736954          DOI: 10.5005/jp-journals-10018-1094

Source DB:  PubMed          Journal:  Euroasian J Hepatogastroenterol        ISSN: 2231-5047


  38 in total

Review 1.  Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation.

Authors:  J Reimann; R Schirmbeck
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

2.  DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates.

Authors:  Zhongming Li; Hongyong Zhang; Xiaoyong Fan; Ying Zhang; Jialu Huang; Qingliang Liu; Torunn Elisabeth Tjelle; Iacob Mathiesen; Rune Kjeken; Sidong Xiong
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

3.  CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Authors:  E Malanchère-Brès; P J Payette; M Mancini; P Tiollais; H L Davis; M L Michel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 4.  Therapeutic vaccination in chronic hepatitis B virus carriers.

Authors:  Stanislas Pol; Marie-Louise Michel
Journal:  Expert Rev Vaccines       Date:  2006-10       Impact factor: 5.217

5.  Role of B cells in antigen presentation of the hepatitis B core.

Authors:  D R Milich; M Chen; F Schödel; D L Peterson; J E Jones; J L Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

6.  A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.

Authors:  Jose C Ferraz; Evangelos Stavropoulos; Min Yang; Steve Coade; Clara Espitia; Douglas B Lowrie; M Joseph Colston; Ricardo E Tascon
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.

Authors:  Maryline Mancini-Bourgine; Hélène Fontaine; Daniel Scott-Algara; Stanislas Pol; Christian Bréchot; Marie-Louise Michel
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

Review 8.  Prime-boost strategies for malaria vaccine development.

Authors:  Susanna J Dunachie; Adrian V S Hill
Journal:  J Exp Biol       Date:  2003-11       Impact factor: 3.312

9.  HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection.

Authors:  D Loirat; M Mancini-Bourgine; J-P Abastado; M-L Michel
Journal:  Int Immunol       Date:  2003-10       Impact factor: 4.823

10.  Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent.

Authors:  D R Milich; D L Peterson; F Schödel; J E Jones; J L Hughes
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more
  1 in total

1.  [Generation of a novel HBeAg transgenic mice using CRISPR/Cas9 technique].

Authors:  Rui Guo; Yi Tian; Xueyuan Jin; Haiyan Chen; Guihu Wang; Xiaozhong Huang; Burong Li; Zongfang Li; Jun Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.